Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Cannabis Investors Are Watching Herbal Dispatch (CSE:HERB) (click to learn more) AI Wellness Stock Targeting Massive Growth (CSE: ALEN.U) (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Plus Therapeutics Inc PSTV

Healthcare Biotechnology
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company’s lead radiotherapeutic candidate is REYOBIQ, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:PSTV)

Plus Therapeutics Provides Business Update on REYOBIQ(TM) Clinical Program and U.S. CNSide® Commercialization

GlobeNewswire January 22, 2026

Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET

GlobeNewswire January 21, 2026

Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering

GlobeNewswire January 14, 2026

Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ(TM) for Leptomeningeal Metastases

GlobeNewswire January 8, 2026

Plus Therapeutics Expands CNSide Assay Platform to State of California

GlobeNewswire December 11, 2025

Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants

GlobeNewswire December 9, 2025

Plus Therapeutics Highlights Three REYOBIQ(TM) Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting

GlobeNewswire December 4, 2025

Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium

GlobeNewswire December 1, 2025

Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ(TM) in Leptomeningeal Metastases

GlobeNewswire November 24, 2025
View More News ››

Opinion & Analysis (NDAQ:PSTV)

Plus Therapeutics Shares Trade Higher on Q3 Earnings and Business Restructuring

Streetwise Reports November 18, 2019

What Stephen Hawking Missed: ...

Streetwise Reports May 2, 2018

Companies flocking to Japan for biotech deals

The Life Sciences Report February 2, 2017
View More Opinion ››

Bullboard Posts (NDAQ:PSTV)

PSTV....Bored me right out of it

Took my profit this a.m GLTA
Iseneschal - June 26, 2025

PSTV...Conference call tomorrow a.m

Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET...
Iseneschal - June 25, 2025

PSTV....a few scalps on this today

No position now Cheers !
Iseneschal - June 25, 2025

PSTV....N.H.O.D 43 ish

Cheers to the Bulls
Iseneschal - June 25, 2025

PSTV.....target is a 40 cent break with volume

That would be very meaningful GLTA
Iseneschal - June 25, 2025

PSTV....ripping in PM on NR

Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of...
Iseneschal - June 25, 2025
View more Bullboard ››

NU E Power Corp.

NU E Power Corp.

NU E is a multi-stage power developer that converts land and grid access into institutional-grade energy assets. NU E ...
View More »

Podcasts